Page last updated: 2024-10-24

folate import across plasma membrane

Definition

Target type: biologicalprocess

The directed movement of folic acid from outside of a cell, across the plasma membrane and into the cytosol. [GO_REF:0000075, GOC:BHF, GOC:hal, GOC:TermGenie, PMID:19762432]

Folate import across the plasma membrane is a complex process involving several steps. It begins with the binding of folate to a specific receptor protein on the cell surface, called the folate receptor. This receptor is highly expressed on rapidly dividing cells, including cancer cells, making it a potential target for cancer therapy. Once bound, the receptor-folate complex undergoes endocytosis, a process where the plasma membrane invaginates and pinches off, forming a vesicle containing the complex. This vesicle then travels to the cell's interior, where it fuses with a lysosome, an organelle containing enzymes that degrade the receptor and release folate into the cytoplasm. Folate is then transported to the mitochondria, where it is used in the synthesis of tetrahydrofolate (THF), a critical cofactor for many metabolic reactions, including DNA synthesis, nucleotide synthesis, and amino acid metabolism. In addition to the receptor-mediated pathway, folate can also be transported across the plasma membrane through a passive diffusion process. However, this process is less efficient and is likely to be of lesser importance compared to the receptor-mediated pathway. Overall, the import of folate across the plasma membrane is a crucial process for cell growth and proliferation, and its dysregulation can lead to various diseases, including folate deficiency and cancer.'
"

Proteins (2)

ProteinDefinitionTaxonomy
Proton-coupled folate transporterA proton-coupled folate transporter that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q96NT5]Homo sapiens (human)
Reduced folate transporterA reduced folate transporter that is encoded in the genome of human. [PRO:DNx, UniProtKB:P41440]Homo sapiens (human)

Compounds (4)

CompoundDefinitionClassesRoles
methotrexatedicarboxylic acid;
monocarboxylic acid amide;
pteridines
abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
10-propargyl-10-deazaaminopterin10-propargyl-10-deazaaminopterin: structure in first source

pralatrexate : A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.
N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound
antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
raltitrexedN-acyl-amino acid
pemetrexedpemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).N-acyl-L-glutamic acid;
pyrrolopyrimidine
antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor